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ABSTRACT 
 
 Human multipotent mesenchymal stromal cells (hMSCs) produce TNF-α-
stimulated gene/ protein 6 (TSG-6).  TSG-6, a hyluronan (HA)-binding protein, has been 
associated with the negative regulation of inflammatory tissue destruction. TSG-6 
modulates proinflammatory cytokine cascades and enhances tissue repair.  The aim of 
this study was to test the effects of recombinant human (rh) TSG-6 on the healing of an 
induced gingival wound within the first 2 days post-surgery.   
 Following gingival resection in one hundred twenty Sprague-Dawley rats (~400 
g), 2 µg recombinant human TSG-6 (rhTSG-6) in 5 µL of Phosphate Buffered Saline 
(PBS) or the same volume of PBS solution was injected into gingival tissue 
approximating the surgical wound.  Control animals did not receive injections.  
Examination of animals occurred at 1-2 hrs, 6-8 hrs, 24 hrs, and 48 hrs post-surgery (n= 
10 per group). Photographs were taken for a double blind clinical assessment at each 
time period.  Tissue biopsy samples (4mm) and blood were collected at 1-2 hrs, 6-8 hrs, 
24 and 48 hrs following surgery.  Specimens were analyzed via histological analysis and 
enzyme-linked immunosorbent assays (ELISA) for quantification and comparison of 
inflammatory markers IL-1β, IL-6, TNF-α and myeloperoxidase (MPO) per treatment 
group.  Weights were recorded for all animals pre- and post-surgery. 
 Animals injected with TSG-6 had significantly less severe inflammation based 
on clinical assessment scores at 6-8 (p=0.01228), 24 (p=0.01675), and 48 hours 
(p=0.0186).  Sham and control animals had more weight loss at 24 and 48 hours.  Based 
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on histological analysis, sham and control animals had more pronounced cellular 
infiltrate.  Animals injected with TSG-6 had significantly less myeloperoxidase (MPO) 
(p=0.027) at 24 hours and IL-1β (p=0.027) at 24 & 48 hours. IL-6 showed marginal 
significant difference at 6-8 hours.  There was no significant difference for TNF-α at any 
time point.    
 TSG-6 reduced post-operative gingival inflammation by modulating the 
inflammatory cascade; reducing levels of proinflammatory cytokines and cellular 
infiltrate. Gingival injection of TSG-6 may offer significant promise as an anti-
inflammatory agent for patients requiring gingival surgery.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
I.1 Inflammation 
Inflammation, a term coined by the ancient Egyptians and Greeks, is commonly 
used today in a variety of clinical settings. The word inflammation comes from the Latin 
word inflammare (to set on fire).  In the 1st century AD., Aulus Cornelius Celsus, a 
Roman writer, described the four cardinal signs of inflammation as calor, dolor, rubor, 
and tumor (heat, pain, redness, and swelling) 1. This definition of inflammation 
recognizes what we know today as the “classical” acute inflammatory response.  Two 
centuries after Celsus, the Greek physician, Galen promoted the idea that inflammation 
(especially pus) was not a superimposed pathology, but rather, part of the beneficial 
response to an injury.  In 1871, Rudolf Virchow postulated that inflammation cannot be 
represented as a single process but rather constitutes various inflammatory processes.  In 
addition, he introduced a fifth element to the four cardinal signs – functio laesa, or loss 
of function, denoting the restrictive function of inflamed tissue 2.  As opposed to Galen, 
Virchow viewed inflammation as innately pathological.  
 The cellular processes and signals that underlie these cardinal signs occur at a 
subclinical level, and therefore solely defining clinical signs and symptoms presents with 
major limitations 3.  It was not until the 19th century, with advances in microscopy and 
cell biology that cell based definitions of inflammation came to the forefront.  Varying 
cell populations stemming from both the blood and local tissue proliferation were being 
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discovered.  We now know that the term inflammation encompasses a multiplicity of 
biological processes.  And with advances in modern molecular biology, becoming 
knowledgeable in the complexities of inflammation at the cellular level has become 
critical to our understanding of how the body reacts to injury, manages insult and 
restores itself to health/function.   
 Inflammation is a defense reaction to the presence of any injurious stimulus.  
Such stimuli include infectious agents, foreign bodies, chemicals, thermal, mechanical 
and immunologic factors. Though there is a great deal of overlap, inflammation can be 
characterized as acute or chronic.  If the cause of the initial injury is not completely 
abolished, acute inflammation will progressively give way to chronic inflammation, 
though there is no definitive time sequence.  
 Acute inflammation refers to a response that is rapid in onset and of short clinical 
duration.  The acute inflammatory response has three major components: hemodynamic 
changes, alterations in the permeability of vessels, and changes in the location and 
concentration of white blood cells 4.  In other words, injury to tissues triggers a specific 
acute response that involves an exudative reaction of fluid, serum proteins, and 
leukocytes that leave the bloodstream to enter the area of injury.  The balance of 
intravascular hydrostatic pressure, which tends to force fluid out of vessels, and osmostic 
pressure, which opposes hydrostatic pressure by plasma proteins is referred to as 
Starling’s Law.  Starling’s Law explains the movement and direction of fluid in and out 
of vessels.  In brief, during the acute inflammatory response, swelling results from both 
an increase in the hydrostatic pressure and the permeability of vessels to plasma 
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proteins.  By leaving the venules and entering the extravascular space, proteins increase 
the osmotic pressure in tissues, drawing more fluid out of the vasculature and into the 
tissues.  The fluid that accumulates in the tissues is termed edema fluid.   Because fluid 
is lost from the vessels while blood cells are retained, the viscosity of the blood 
increases, which slows the movement of blood to the site of injury where supplies are 
needed.  Active hyperemia, a process of increased “trafficking” of fluid and proteins 
results in dilation of arterioles at the site of injury due to congestion of blood and 
proteins within the microvasculature 5.  When these vessels dilate, the cells of the 
endothelium contract to form gaps between the cells through which fluid and plasma 
proteins can move.  Plasma proteins that leave through these gaps include albumin, 
fibrinogen, immunoglobulins, and other high molecular weight proteins.   
 Chronic inflammation is characterized by an increasing production of small 
blood vessels, fibroblasts, in addition to an infiltration of chronic inflammatory cells 
such as lymphocytes, macrophages, and plasma cells.   Collectively, these elements 
comprise chronic inflammatory tissue.  T-helper cells and the macrophage are the key 
cells in initiating a chronic inflammatory response.  Therefore, chronic inflammation is 
basically an immune response initiated in response to a persistent antigen; a response 
that persists for more than a few days or weeks.  It is often associated with irreversible 
destruction of normal parenchyma, inducing a phasic process of destructive mechanisms 
(inflammatory-degenerative) and healing (scar tissue).   Over time, this course may 
result in permanent loss of function in the affected parts of the body.  Chronic 
inflammation may go unnoticed by patients because pain is often minimal or absent.  
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The cardinal signs (heat, pain, redness, and swelling) often prominent in acute 
inflammation are nominal in chronic inflammation.  It differs from acute inflammation 
in that it is predicated almost entirely by cells of the immune system.     
 Pro-inflammatory immune mediators [cytokines, chemokines, C-reactive protein 
(CRP)] are generated from either cells or from plasma proteins.  The liver proteins, 
plasma-derived mediators (e.g., kinins, complement proteins) present in the circulation 
as inactive precursors.  These precursors must be activated by a series of proteolytic 
cleavages, in order to procure their biologic properties.  The three interrelated enzyme 
systems which mediate vascular permeability and are involved in peptide formation, are 
the kinin, fibrinolytic, and complement systems.   Hageman factor (XII), a key 
component of the blood clotting system, triggers both the kinin and fibrinolytic systems.  
Once activated, either during injury when it binds to damaged blood vessels or upon 
proteolytic cleavage by kallikrein and LPS, it converts prekallikrein to kallikrein, 
activating more Hageman factor.  Kallikrein is a protease, cleaving kininogen to produce 
bradykinin.  Bradykinin is capable of increasing the permeability of venules,  inducing 
arteriolar dilation and thus cause pain 6.     After forming a blood clot at the site of 
injury, the fibrinolytic system becomes activated to dissolve the clot.  Fibrinogen is 
released from platelets after they adhere to sites of endothelial cell injury.  Thrombin 
converts fibrinogen to fibrin.  The generation of thrombin promotes platelet aggregation 
and secretion of inflammatory mediators by platelets.  The fibrinolytic system also 
involves the activation of plasminogen to generate plasmin.  Plasmin can cause 
vasodilation, digestion of fibrin, split activated Hageman factor into subunits that turn on 
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the kinin system, and can activate the complement system by cleaving C3 to produce C3 
fragments 7.  Once activated, complement becomes a powerful effector  that mediates 
vascular responses to  recruit phagocyctic leukocytes, opsonizes targets of phagocytic 
cells and directly injures target cells or tissues 5.  The complement system is made up of 
over 25 proteins and protein fragments found in the blood, normally circulating as 
inactive precursors and plays a key role in many acute inflammatory processes and host 
defenses.    When stimulated, specific proteins are cleaved by proteases to release 
cytokines.  These activated proteins can then initiate an amplifying cascade of further 
protein cleavages and cytokine release.  The end result is the activation of the cell killing 
membrane attack complex (C5,6,7,8, and 9) which is directly responsible for the lysis of 
foreign organisms 8.  The three biochemical pathways that stimulate the activation of the 
the complement system include the classic, alternative, and lectin pathway.  The 
classical pathway involves antigen:antibody complexes for activation, whereas the 
alternative and lectin pathways can be activated by C3 hydrolysis or antigens alone; 
without antibodies present.  In all three pathways, C3 becomes activated, producing 
products C3a and C3b.  C3a, called anaphylatoxin, causes mast cells and basophils to 
release histamine, resulting in vasodilation and increased vascular permeability.  C3b 
binds to the surface of pathogens, facilitating opsonization for greater internalization by 
phagocytic cells9.   
 This elaborate system is illustrated in the following diagram.    
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Figure 1. Model of the Complement Cascade. 
10   
              The complement system  is by far the most important of the plasma protein 
systems of inflammation.  Once it becomes activated, its constituents participate in 
virtually every inflammatory response. 
 Cell-derived mediators of inflammation are normally appropriated in intracellular 
granules.  These mediators can be secreted promptly by granule exocytosis or can be 
synthesized de novo (e.g., prostaglandins, cytokines) in response to a stimulus.  Platelets, 
neutrophils, monocytes/macrophages, and mast cells are the major cell types that 
produce mediators of acute inflammation 4.  The local production of mediators, such as 
TNF-α, IL-1β, IL-6, and PGE₂  that occur within inflamed tissues may “spill” into 
circulation.  Its circulatory involvement may prompt systemic sequela, such as induction 
of endothelial dysfunction 11.  Pro-inflammatory cytokines in circulation induce 
leukocytosis and  production of acute phase proteins.  Acute phase reactants include 
 7 
 
fibrinogen, serum amyloid A protein, plasminogen activator inhibitor 1, complement 
proteins, lipopolysaccharide binding protein and soluble CD14 12.   
 Cytokines are low molecular weight proteins produced by inhabitant cells, such 
as epithelial cells, fibroblasts, phagocytes (neutrophils and macrophages), and immune 
cells (lymphocytes) and are associated with both the acute and early chronic phase of 
inflammation as well as in adaptive immunity13.  Cytokines propagate inflammation, and 
regulate the extent and amplitude of response.   IL- 1β and IL-6 are signature innate 
cytokines that have well documented associations with inflammatory cell migration and 
osteoclastogenesis 14. IL-1β exerts a range of inflammatory and immunomodulatory 
activities.  It is produced primarily by monocytes and macrophages and also by T cells, 
natural killer (NK) cells, endothelial cells, fibroblasts, astrocytes, microglial cells, 
adrenal cortical cells, and pancreas β-cells 15.  It is a pleiotropic cytokine involved in 
host responses to microbial invasion, inflammation, immune regulation, metabolic 
reactions, hematopoietic processes and tumor progression 16.  It affects important cellular 
functions, such as decreasing protein synthesis and intracellular energy production, 
reducing DNA contents, and prompting β-cell apoptosis and necrosis 17.  A complex 
system of IL-1 family members and receptors tightly regulates IL-1β expression and 
function.  It can activate a complex cascade resulting in signal amplification, 
transcription factor induction, and other cellular activities, including cell proliferation, 
differentiation, and apoptosis that play a pathophysiologic role in host protection and 
inflammation 18.  In addition, IL-1 is a key cytokine involved in extracellular matrix 
degradation.  It had been up-regulated in patients with  rheumatoid arthritis, 
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osteoarthritis, periodontitis and other inflammatory diseases and conditions 19.  
Interleukin-6 (IL-6) is a potent, pleiotropic Th2 (type 2 helper T cell) cytokine that 
regulates the immune defense response.  It plays a role as both an anti-inflammatory and  
pro-inflammatory cytokine.  It also plays a central role in the transition from the acute to 
the chronic phase of the inflammatory process.  Elevated levels have been documented 
in an assortment of autoimmune diseases, such as inflammatory bowel disease, systemic 
lupus, rheumatoid arthritis, glomerular nephritis, etc. 20.  Overproduction of IL-6 leads to 
the deposition of extracellular matrix proteins, development of inflammatory lesions and 
synthesis of acute phase proteins.  TNF-α is a pleotropic cytokine that has many 
functions such as cell migration and tissue destruction21.  TNF-α also degrades 
extracellular matrix and causes bone resorption by acting to secrete matrix 
metalloproteinases (MMPs) and receptor activator of nuclear factor kappa-B ligand 
(RANKL) as well as up-regulating the production of IL-1β and IL-6 22.   
  Resident  macrophages, mastocytes, dendritic cells, Kupffer cells, and 
histiocytes  present certain receptors known as Pattern Recognition Receptors (PRRs) on 
their surface that are able to recognize molecules foreign to the body, collectively 
referred to as pathogen-associated molecular patterns (PAMPs).  Upon injury, these cells 
undergo activation, whereby a pattern recognition receptor recognizes a pathogen-
associated molecular pattern, causing a release of chemical mediators 23.  Chemical 
mediators each have a specific function at some definite phase of the inflammatory 
reaction.   
 Upon stimulus, these chemical messengers intensify and propagate the 
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inflammatory response influencing, these previously described, vascular and 
hemodynamic changes.  Following a brief period of vasoconstriction, arterioles dilate 
and the microvasculature at the site of injury becomes engorged with blood cells. With 
increased vasopermeability, blood flow to the wounded area can increase in as much as 
ten-fold 5.  Plasma proteins, such as albumin, fibrinogen, and globulins leak into the 
extravascular compartment. As these proteins leave the vessels and enter the 
extravascular space, they increase the osmotic pressure in the tissue, drawing more fluid 
out of the vasculature and into the tissues; a process which facilitates vascular stasis.  
Vascular stasis describes an eventual complete stagnation of blood flow due to increased 
vascular permeability and hemoconcentration.    
  Selective migration of blood leukocytes to the site of inflammation occur by 
margination, diapedesis, and chemotaxis.  During margination, leukocytes accumulate 
and adhere to the endothelial cells of blood vessels that occur at the site of injury.  
Adherence involves the interplay between specific adhesion molecules present on the 
surfaces of leukocytes and endothelial cells.  Certain inflammatory mediators such as IL-
1, TNF-α, chemotactic factors, and histamine stimulate the activation of these adhesion 
molecules.  As white blood cells travel across the endothelium, a process known as 
diapedesis, they become part of the interstitial fluid.  Interstitial fluid envelops blood 
vessels and tissue cells.  The response of leukocytes to products formed during 
immunologic reactions, involves adherence and accumulation at the site of the reaction.  
Emigration and subsequent migration of white blood cells through tissue are due to 
chemotactic factors. Chemotaxis, therefore, is a cellular function that stimulates the 
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direction of migration of cells via chemical stimulus 5.    
 The vascular changes and accumulated inflammatory exudate often result in 
clinical signs present on the skin.  These changes, which consist of a flush, flare, and 
wheal, are referred to as the “Triple Response of Lewis” 5, and can be characterized by: 
1) An immediate reddening, or flush, due to vasodilation; 2) A red flare that surrounds 
the injured area and spreads outward; and 3) A swelling, or wheal, as edema fluid 
collects due to increased vascular permeability.  The substances that leave the vessels 
and enter the tissues are collectively called the exudate. 
 The amount of protein in an exudate is variable.  Serous exudate is characterized 
as clear with low protein content and limited cells.  This type of exudate is primarily 
associated with mild inflammation.  Fibrinous exudate is rich in protein, especially 
fibrinogen.  It typically forms a clot once it enters tissue, due to the formation of fibrin.  
Suppurative (or purulent) exudate is rich in neutrophils (PMNs) and is typically 
recognized as pus.   
 The duration of vascular response is controlled by chemical mediators and can be 
identified as an immediate, delayed, or sustained response.  Immediate transient vascular 
responses last about 10-15 minutes, and it is mediated primarily by histamine.  
Immediate prolonged responses occur with more severe injury and may last for hours or 
even days 5.  Chemical mediators include bradykinin, prostaglandins, leukotrienes, 
anaphylatoxins, oxygen-derived free radicals, etc.  Delayed prolonged response to injury 
does not evoke and immediate response.  This response is mediated by prostaglandins 
and leukotrienes.  In the severest of injuries, a sustained response ensues, which involves 
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a marked vascular response comprising venules, capillaries, and arterioles. Vascular 
permeability immediately increases and remains high over a prolonged period of time.  
This type of response is mediated by all chemical mediators previously mentioned and 
involves an overlapping of the immediate (histamine-mediated) and delayed responses.   
 The events of the vascular response to injury, which include monocyte release of 
polypeptide cytokines and growth factors from peripheral blood, aim to concentrate and 
eradicate the injurious agents and eliminate damaged tissue constituents so that the body 
can begin to heal.  The response, however, consists of alterations in blood flow, an 
upsurge in blood vessel permeability, and movement of fluid, proteins, and leukocytes 
from circulation to the site of tissue impairment.  Collectively, these events explained by 
the behavior of the underlying cells and tissues, form the basis of which the Ancient 
Greeks and Romans derived their cardinal signs of inflammation centuries ago. 
 The immune system comprises a network of cells, tissues, and organs, highly 
specialized in defending our body against microbial invaders.  Open bodily wounds 
serve as a conduit for invading pathogens, that to which our immune system must 
respond.  In the field of medicine and dentistry, surgical insults, via blades, needles, 
lasers, etc.  are made routinely upon rendering treatment.  Subsequently, these initial 
acute wounds destroy cells, triggering the automatic response to injury and initiating the 
inflammatory cascade. 
            I.2 Gingivectomy 
 In the field of dentistry, specifically, periodontics, surgical procedures involve 
cutting or removing soft or hard tissues of the support structure to the teeth.  According 
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to Genco and Rosenberg, the main objectives of periodontal surgery include: to gain 
surgical access to deep or tortuous pockets, to facilitate plaque control, to provide an 
environment for an adequate prosthesis, for periodontal regenerative therapy, and to 
correct cosmetic abnormalities 24. To provide access for thorough debridement of the 
tooth surfaces, surgical flaps, gingivectomy, and osseous contouring procedures are 
sometimes necessary.  Hyperplastic or enlarged, fibrous gingival tissues often become an 
area of deep probing depths.  These deep areas often serve as plaque retention areas and 
resective procedures help reduce bioburden.  Periodontal surgical procedures such as 
crown lengthening, alveolar ridge augmentation, and correction of mucogingival defects 
help reduce inflammation and periodontal destruction. Resection of soft and hard tissues 
of the periodontium exposes subgingival margins of existing defective crowns or carious 
lesions.  Gingivectomy or gingivoplasty often eliminates clefts, recontours bulbous 
gingiva and exposes the crowns of teeth that appear anatomically short, as occurs in 
altered passive eruption.  As with most surgical procedures, each treatment mentioned 
would necessitate gingival incisions for access to root surfaces and bone.  
 Historically, periodontal procedures aim at reducing or eliminating pocket depths 
via resective procedures.  The earliest form of resection was the gingivectomy.  In 1792, 
Pierre Fauchard, now referred to as “the father of modern dentistry,” described the 
procedure and designed instrumentation specific to the removal of gingiva 25.  Over a 
century later, in 1884, Robicsek described a similar technique of gingival excision and 
granulomatous tissue elimination 26.   Pickerill in 1912 called this procedure 
‘gingivectomy’ 27.   
 13 
 
 A gingivectomy attempts to remove the soft tissue wall of the periodontal pocket 
by an external bevel incision that leaves a cut surface exposed to the oral cavity 24.  As 
illustrated by Goldman in 1951, the primary incision is begun as far apically to the 
pocket depth as possible to achieve a long bevel 28.  The gingiva is excised down to the 
base of the pocket.  The epithelial attachment is removed during this process, leaving 
only a portion of the connective tissue of the gingival corium coronal to the alveolar 
crest 29.  The knife is then extended deep into the interproximal areas so as to sever the 
existing papillae.  The initial incision is made with a surgical knife or blade, extending 
interproximally as far as possible.  After this is accomplished, the tissue is generally 
loosened and can easily be removed using a scaler or curette, as illustrated in the 
following pictures. 
                                                
Figure 2. Gingivectomy Procedure.
78    
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             Gingivectomy procedures are common with most periodontal procedures such as 
elimination of diseased tissue or other resective procedures such as crown lengthening.   
 In the case of open wounds, as in the gingivectomy procedure, many gingival 
vessels are severed and exposed.  The gingival vasculature has been extensively studied 
in health and inflammation.  Nuki and Hock evaluated vascular perfusion and vessel 
arrangement in cats and dogs 30.  The gingival vasculature consisted of a microvascular 
bed, containing arterioles and precapillary venules.  Numerous capillaries were found 
within the crestal gingiva, precapillary arterioles and postcapillary venules within the 
midgingival region, and small arterioles and venules predominated apical gingiva.  The 
entire gingival vascular bed was affected with increasing severity of inflammation. 
Changes in vessel diameter and length as well as distortions of connecting capillaries 
and vessel loop formations were all observed.  In 1963, Novaes and Kon studied the 
gingival and periodontal microcirculation during various phases of healing following the 
creation of a variety of surgical wounds in dogs 31.  Gingivectomies were carried out on 
the labial side of the lower incisors.  Intra-arterial injection with filtered Pelikan carbon 
black suspension was performed prior to animal sacrifice.  Immediately after surgery, 
large vessels which had been cut were observed in direct contact with the surface of the 
wound.  This was evident as the perfused material was released subjacent to and on the 
surface of the wound.  By day -2, the specimen showed a thick clot covering the entire 
wound, bringing about an outer smoother surface.  The connective tissue observed was 
dense and cellular, but showed little inflammation.   
 Epithelialization of the wound surface following gingivectomies in rats was 
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observed by Fredderick Henning in 1968 32.  By 24 to 48 hours, they found early 
epithelialization of the wound surface by migration of cells derived from the oral 
epithelium into the coagulum.  “Reattachment”, however, was not achieved until 15 to 
21 days after wounding and about 10 days after completion of epithelialization of the 
wounds.  Upon histologic examination following gingival injury in a rat model, Stahl 
and Person found that the inflammatory response appeared prominent 24 to 48 hours 
after injury and the wound seemed epithelized 5 to 7 days post injury 33.  Others found a 
blood clot and neutrophil leukocytes covering the wounded surface at 24 hours 
following ginigvectomy in the rat.  After 48 hours, the epithelium began to migrate from 
the remaining keratinized oral epithelium 34.  Grevstad et al. reported similar 
observations 35.  After performing interdental incisions to obtain a complete surgical 
transection of the gingival tissue in young albino rats, healing was evaluated via light 
and electron microscopy.  At 24 hours, accumulations of  inflammatory cells, were 
primarily found within the wound space.  At the wound margins, striated fibrin strands 
appeared as remote, amorphous fragments along fiber bundles.  In fact, for both 
incisional wounds of the gingiva and gingivectomies, within hours of injury, epithelial 
cells along the wound margins begin to migrate.  Migration results  from stimuli induced 
by locally released factors such as  platelet-derived growth factor  or epidermal growth 
factor and other cytokines 36.  Upon injury, cells travel over the unprotected connective 
tissue surface releasing collagenase and plasminogen activator to boost collagen 
remodeling and promote dissolution of  the fibrin clot formed 19.  Within the initial 
phases of healing from a gingivectomy wound (days 1-2), the migrating epithelial 
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exterior  is only 2-3 cells thick and forms a stratum basale.  By day 5, complete coverage 
of the wound is observed and by day 7 a new stratum corneum is present as evidenced 
by matured epithelium 37.           
  Healing is commonly divided into three overlapping phases: 1) inflammation; 2) 
granulation tissue formation; and 3) matrix formation and remodeling.  Neutrophils and 
macrophages dominate the early and late phases of inflammation, respectively 38.  
Within hours of injury, these inflammatory cells inhabit the clot to debride the wound of 
pathogens and necrotic debris through phagocytosis and formation of enzymes and toxic 
oxygen products.  And though polymorphonuclear leukocytes can abolish toxic 
substances and provide protective mechanisms, these cells can also synthesize 
collagenases, acid hydrolases and neutral proteases that participate in destroying host 
tissue 39.  These substances can break down collagen, proteoglycan ground substance 
and connective tissue.  
 I.3 Cellular Components 
   Neutrophils, the most abundant of the leukocytes and the first to infiltrate 
tissues in the early stages of an acute inflammatory response, are myeloid-derived anti-
microbial professional phagocytes than can also execute pathogens extracellularly, link 
the innate and adaptive arms of the immune response, and help promote inflammatory 
resolution and tissue healing 40. The human neutrophil originates from a precursor pool 
of committed progenitor cells and is followed by two secretory stages: the promyelocyte 
and the myelocyte.  During each of these stages a distinct type of secretory granule is 
produced – azurophils (solid black) during the promyelocyte stage, and specific granules 
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(light forms) during the myelocyte stage 41.  During the course of differentiation in the 
bone marrow, all of the blood granulocytes synthesize and package into secretory 
granules a number of enzymes (some with digestive and antibacterial abilities) and other 
substances. The mature form of the neutrophil is characterized by a multilobulated 
nucleus and cytoplasm containing primarily glycogen and granules 4. After the 
myelocyte stage, cells are released into the blood where they circulate and migrate to 
tissues, killing and digesting pathogens. They are the most common cells found at the 
sites of inflammation.  
 Neutrophlic differentiation and maturation are stimulated by a cytokine, 
granulocyte colony-stimulating factor, elaborated by activated macrophages.  
Macrophages, a key participant in the mechanisms of host defense, are ultimately 
derived from bone marrow precursors.  They spend a brief time in the blood stream as 
circulating monocytes before taking up their definitive location as mature macrophages.  
The earliest recognizable forms are the replicating monoblasts and promonocytes.  Like 
granulocytes, monocytes form granules during differentiation in the bone marrow.  
Monocyte granules, however, are smaller than those of the neutrophils and 
comparatively inconspicuous.  Monocytes differentiate very rapidly in marrow (1-3 
days), usually undergoing from 1 to 3 divisions before entering the blood, where they 
circulate for about 1 day 42.  One of the most critical steps in their life history is their 
delivery to tissue sites both within and outside of the vasculature, where they further 
differentiate, within a day or so, into long-lived (60-120 days) and versatile 
macrophages4.  
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 On the basis of function, the blood leukocytes are usually divided into two main 
groups: the phagocytes, such as granulocytes and monocytes; and the nonphagocytes, the 
lymphocytes.  The granulocytes include the polymorphonuclear neutrophil (PMN) [50-
70% in blood], the eosinophils [1-5% in blood], and the basophil [0-1% in blood].  The 
lymphocyte [20-40% in blood] and monocyte [1-6% in blood] comprise the 
mononuclear cells.  Of the phagocytes, the neutrophils and monocytes (macrophages) 
play a major role in host defense.  These cells are discriminatory and efficient in their 
ingestion, and effectively destroy invaders intracellulary.  The term phagocytosis 
describes the process of engulfment and ingestion of large particles by the cell or 
phagocyte to form a phagosome (or food vacuole), which in turn fuse with lysosome and  
become phagolysosome.  The engulfed material is eventually digested or degraded and 
either released  intracellulary to undergo further processing or extracellularly via 
exocytosis..  With their phagocytic properties, neutrophils along with the other pro-
inflammatory cells, propagate the swelling and edema often experienced after a surgical 
procedure.   
 I.4 Current Therapies 
 Efforts to control inflammation to date have been focused on the use of 
pharmacological agents that inhibit pro-inflammatory mediator pathways.  Non-steroidal 
anti-inflammatory drugs (NSAIDs), for example, target COX-1 and COX-2-dependent 
pathways inhibiting generation of prostanoids.   Newer classes of inhibitors target 
lipoxygenase pathways and leukotriene (LT) production or TNF-α.  Side effects of these 
agents, however, prohibit their extended use.  Glucocorticoids are the most effective 
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anti-inflammatory drugs currently available for treatment of chronic inflammation.  The 
mechanisms by which they effect repression of inflammatory gene expression remain 
incompletely understood.  Glucocorticoids reduce the expression of chemokines, 
cytokines, inflammatory enzymes, adhesion molecules, and other inflammatory proteins, 
lowering the inflammatory cell burden 43.  They exert their anti-inflammatory actions via 
a complex interplay between glucocorticoid receptor (GR)- mediated transcriptional 
regulation and signal transduction within target tissues 44.  Glucocorticoids target 
specific cell populations to combat hyperactivation of the immune system, at both the 
transcriptional and cellular level.  Corticosteroid complications, however, include 
metabolic derangements (particularly hyperglycemia), adrenal insufficiency, and critical 
illness myopathy 45.  Dexamethasone, a steroid medication often given post-surgery via 
IM, IV, or oral administration to reduce inflammation also suppresses the body’s usual 
immune response.  Side effects include stomach irritation, vomiting, headache, 
dizziness, insomnia, muscle weakness, depression, anxiety, vision problems, absent or 
irregular menstrual periods, etc.  
  With the progression of research in the field medicine, however, scientists are 
well on their way to finding more innocuous ways to reduce or eliminate this 
inflammatory response, so often causing pain and discomfort to patients alike.  In 
procedures such as gingivectomies, gingivoplasties, or crown lengthening where a 
laceration induces an acute inflammatory response, tissue repair is of paramount 
importance to post-operative wound healing and patient well-being.      
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I.5 MSCs 
 Human adult stem/ progenitor cells from bone marrow, referred to as 
mesenchymal stem cells or multipotent mesenchymal stromal cells (hMSCs), have been 
at the forefront of modern research.  They are of interest because they can readily be 
isolated from human donors or patients, expand rapidly for 30 or more population 
doublings in culture, and differentiate into several cellular phenotypes in vitro and in 
vivo.  These and related properties prompted testing the therapeutic potential of the cells 
in animal models and in clinical trials for a large number of diseases 46.  Throughout 
their course of study, evolving data has led to the development of various hypotheses 
regarding their role in wound repair.   Prockop (2011), identified MSCs as ‘guardians of 
inflammation,’ and summarized the shifts in paradigms.  Initially, the cells were thought 
to provide a niche for culture of hematopoietic cells.  Cells were then reconnoitered as 
reparative cells that might engraft and differentiate to replace injured cells.  Engraftment 
and differentiation was observed in rapidly growing embryos, after local administration 
of large concentrations of the cells or after extreme injury.  However, repair of tissues 
and functional improvements were more frequently observed without long-term 
engraftment of MSCs.  More recently, data suggest that the cells only transiently appear 
in injured tissues under most conditions, but while present, respond by paracrine 
secretions or cell-to-cell contacts/ cross-talk with injured cells to limit tissue destruction 
or enhance repair by a variety of mechanisms 47, 48.  These mechanisms include 
upregulating genes that can modulate excessive inflammatory and immune reactions and 
enhance proliferation and differentiation of other stem cells.  Among these therapeutic 
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factors, MSCs express the multipotent anti-inflammatory protein tumor necrosis factor 
(TNF)-α-stimulated gene/protein 6 in response to tissue injury.   
I.6 TSG-6 
 TNF-α-stimulated gene/ protein 6, or simply TSG-6, is a hyluronan (HA)-binding 
protein that has since been implicated in the negative regulation of inflammatory tissue 
destruction.  TSG-6 DNA was originally isolated from a cDNA library prepared from 
TNF-α - treated human fibroblasts 49.  It is secreted by different cells, such as fibroblasts, 
upon stimulation by the proinflammatory cytokines tumor necrosis factor or interleukin-
1. 
I.6.1 Structure 
 The TSG-6 protein has a molecular mass of  ~35 kDa.  The solution structure of 
the link module was identified by Kohda et al. via NMP spectroscopy, revealing a 
compact fold containing two α-helices and two anti-parallel β-sheets, each comprising 
three β-strands 50.  This link module of TSG-6 shows varying degrees of homology to 
members of the hyaladherin family of proteins.  The N-terminal half of the TSG-6 
protein (the link module) binds various glycosaminoglycans (GAGs), including HA, 
chondroitin sulfate, heparin, and heparin sulfate.  Its amino acid sequence shows 36-40% 
identity with members of the hyaladherin family, including the CD44 receptor, cartilage 
link protein, and proteoglycan core proteins 49. 
 CD44 is identical to the hyaluronate receptor, mediating the adhesion of a variety 
of different cells to HA in the extracellular matrix and on cell surfaces 51, 52.  CD44 is 
expressed on a large variety of mammalian tissues mediating many different cell 
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adhesion events involving cell-cell interactions 51.  Aggrecan, the proteoglycan core 
protein and link protein are important structural components of the extracellular matrix.  
Versican, the closely-related proteoglycan core protein of fibroblasts, and aggrecan 
contain at their amino terminus HA binding motifs 53.  In cartilage, these core proteins 
form a ternary complex with both HA and link proteins, which determine the structural 
integrity of the extracellular matrix of cartilage 54. 
 The C-terminal half of TSG-6 forms a CUB domain, a structure that has been 
defined exclusively on the basis of homologies and certain structural elements.  The term 
CUB domain is derived from the initials of three representatives of the family that 
reflects the diversity of this group: the complement components C1r and C1s are serine 
proteases, Uegf – a gene involved in the development of sea urchin embryos, and bone 
morphogenetic protein 1 (BMP-1) – a metalloproteinase 55.  The structure of the CUB 
domain of TSG-6 has not been solved, however, it is likely that the CUB domain of 
TSG-6 shares the general structural features of those CUB domains whose 3D structures 
have been identified.  Among these, β-sheets have been found around 15 hydrophobic 
and 4 aromatic amino acid residues that form the core of the CUB domain.  It is 
presumed that the CUB domain structure found within TSG-6 is similar in structure.  In 
addition, two disulfide bridges, which have been identified among most other CUB 
domains, have been found within the putative CUB domain of TSG-6 56.  So far, no 
functions other than involvement in protein-carbohydrate and protein-protein 
interactions have been attributed to the CUB domain. The limited sequence homology 
between the CUB domains of various proteins precludes conclusions about any 
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particular binding specificity.  To date, only fibronectin has been shown to bind to the 
CUB domain of TSG-6 57.  TSG-6 is unique in that it possesses both a link module and a 
CUB domain. 
I.6.2 TSG-6 Expression 
 TSG-6 is not expressed constitutively in unstimulated cells or tissues; its 
expression can be induced in response to a variety of factors.  The rapid upregulation of 
TSG-6 in the presence of the pro-inflammatory cytokines TNF and IL-1 is consistent 
with its involvement in inflammatory processes 58.  This association was confirmed by 
the detection of TSG-6 protein in synovial fluids of patients with a variety of conditions 
including rheumatoid arthritis, osteoarthritis, Sjögren’s syndrome, polyarthritic gout, and 
osteomyelitis 59.  TSG-6 has not been detected in synovial fluids obtained at autopsy 
from accident victims with no known joint disease.  Both chondrocytes and articular 
synovial cells, isolated from patients with rheumatoid arthritis, were shown to produce 
TSG-6 in culture.  When stimulated with IL-1 or TNF in vitro, both cell types produced 
increased amounts of TSG-6 60.  Additional studies have confirmed the expression of 
TSG-6 in human chondrocytes, demonstrating TSG-6 in IL-1-stimulated chondrocytes 
obtained from patients with osteoarthritis 61, 62. 
 The first indication of an anti-inflammatory activity of TSG-6 came from a study 
using recombinant human TSG-6 protein in the murine air pouch model of acute 
inflammation.  Wisniewski and colleagues examined the effects of TSG-6 on 
experimentally induced inflammation.   Recombinant TSG-6 protein, injected together 
with a pro-inflammatory agent, e.g. carrageenan or IL-1, into the air pouch lumen 
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revealed an inhibitory effect of the locally administered TSG-6 on the IL-1-induced 
cellular infiltration.  When compared to that of systemic dexamethasone treatment, TSG-
6 proved to be as effective as dexamethasone in inhibiting IL-1-induced neutrophil 
infiltration.  Histological analysis of the air pouch lining and the underlying tissue 
showed that TSG-6 treatment resulted in a significant resolution of the edema and of the 
tissue destruction induced by the injection of carrageenan 63.  
 Minrescu et al. 64 examined the effect of recombinant TSG-6 on inflammatory 
joint disease induced in DBA/1K mice.  Mice receiving the CIA (collagen induced 
arthritis) immunization were given twelve intraperitoneal doses of TSG-6, three days 
before the expected onset of the disease symptoms.  They found that there was a 
decrease in the disease incidence, arthritis index, and footpad swelling in TSG-6 treated 
animals, producing a potent ameliorative effect.    
 In 2009, Lee and colleagues, studied the anti-inflammatory effects of human 
mesenchymal stem cells in a model of myocardial infarction.  hMSCs were infused i.v. 
in a mouse model with ligation of the anterior descending coronary artery.  They found 
that the i.v. injection significantly reduced the early inflammatory response and size of 
the myocardial infarcts.  Three weeks later, significant improvements were also observed 
in left ventricular function as observed by echocardiography.  Quantitative assays, 
however, demonstrated that only a small fraction of the infused MSCs were recovered in 
the heart after injection and within 24 hrs.  There was an absence of stem cells by 48 
hours.   RNA was extracted from the mice 10 hours after infusion and was assayed.  It 
was found that the hMSCs were activated to upregulate the expression of over 50 human 
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genes.  Among these was TSG-6.  In an effort to study the role TSG-6 played, they 
infused hMSCs with an siRNA knockout of the TSG-6 gene into the mouse.  In this 
model, they found that the hMSCs had little or no effect in the MI model.  Results of the 
experiment demonstrate that hMSCs were activated to secrete TSG-6, and the TSG-6 
decreased the early and excessive inflammatory response in the heart that caused the 
destruction of cardiac tissue 65.   
 In a subsequent article published in 2011, Gavin Roddy and colleagues, 
demonstrated that systemically administered hMSCs reduced inflammatory damage to 
the cornea without engraftement and primarily by secretion of TSG-6 in response to 
injury signals from the cornea.  Similar therapeutic effects were reproduced by i.v. or 
topical administration of TSG-6.  Corneas of six-week-old male Lewis rats were injured 
by brief exposure to alcohol followed by mechanical debridement of the corneal and 
limbial epithelium with a surgical blade.  Immediately following injury, rats either 
received hMSCs via i.v. or i.p.  Other rats were treated with siRNA for TSG-6.  Others 
received topical application of 8µg of rhTSG-6 in 20µL PBS or PBS alone.  Results 
revealed i.v. infused hMCs markedly decreased neutrophil infiltration, production of 
proinflammatory cytokines, and development of opacity in the cornea 48.   
Infusion, via i.p. of the hMSCs was also effective in subduing inflammation and 
preventing the opacity in the cornea.  <10 hMSCs were present in the corneas of rats at 
day 1 and 3 after i.v. or i.p. administration.  Those rats that received the siRNA 
knockdown of the TSG-6 gene showed no effective healing of the cornea.  To test that 
signals from injured corneal cells would activate hMSCs to express TSG-6, hMSCs were 
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co-cultured with human corenal epithelial cells injured with ethanol.  They found that 
TSG-6 expression was increased approximately 13-fold in hMSCs.  TSG-6 secretion by 
hMSCs was therefore both necessary and sufficient to reduce corneal inflammation.  
These results are consistent with those previous findings that i.v. injection of hMSCs 
secreted TSG-6 to improve cardiac function by decreasing inflammation in a mouse 
model of myocardial infarction 65.   
 A related series of experiments validated that direct injection of rhTSG-6 into the 
anterior chamber of the rat eye also decreased excessive inflammation in the injured 
cornea.  In a recent study by J. Oh and colleagues, 2 µg recombinant human TSG-6 or 
PBS solution was injected into the anterior chamber of rats’ eyes that were exposed to 
chemical and mechanical injury 66.  The eyes injected with the TSG-6, had markedly 
reduced inflammatory damage, attributed to the ability of TSG-6 to inhibit proteases and 
to suppress neutrophil migration into the site of inflammation.  The levels of 
proinflammatory cytokines, chemokines, and matrix metalloproteinases were also 
decreased.  To study a dose response to the therapy, varying doses of TSG-6 (0.0002-
2µg) were injected into the anterior chamber of the eyes immediately following injury.  
A dose-dependent response was observed, as significant improvements in the anti-
inflammatory effects were associated with higher concentrations of TSG-6.  To 
investigate the window of opportunity for TSG-6 to be administered following an acute 
injury, 2µg TSG-6 or PBS solution at different time points (0-24 hours) after injury was 
administered.  Injection within 4 hours after injury significantly decreased inflammation 
in the cornea.  The same results were seen when injection was delivered 2 hours after 
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injury.  TSG-6 was not effective, however, if administered 8 – 24 hours after injury, at 
which time neutrophils had intensely infiltrated the cornea.  The mechanism by which 
TSG-6 inhibits neutrophil invasion has not been well-defined.  Several reports suggest 
an inhibition of the migration neutrophil extravasation of neutrophils by down-regulating 
the protease network; specifically mediated by its potentiation of inter-α-inhibitor anti-
plasmin activity 67, 68.  Plasmin has an important role in the proteinase cascade activated 
during inflammation which results in extracellular matrix degradation and cellular 
infiltration.  The anti-inflammatory activity of TSG-6 was attributed to its ability to 
inhibit components in the inflammatory network of proteases and to suppress neutrophil 
migration into the site of inflammation 69.  
 TSG-6, secreted by activated MSCs following injury, has thus been found to 
modulate the cascade of proinflammatory cytokines and enhance tissue repair 47.  The 
mechanism of action observed by the anti-inflammatory effects of TSG-6 is not well 
understood.  However, in recent studies, Inter-α-inhibitor, an abundant plasma protein 
with anti-proteolytic activity, consisting of three polypeptides: two heavy chains and one 
light chain, has been shown to bind to hyaluronon molecules via covalent bonds, a 
reaction thought to be mediated by TSG-6.  TSG-6 has been shown to be tightly bound 
to the hyaluronon-linked heavy chains.  This complex has been implicated in stabilizing 
extracellular matrix by cross-linking hyaluronan molecules and protecting hyaluronan 
against fragmentation by reactive oxygen species, enhancing tissue repair 70.  Though the 
anti-inflammatory properties are likely to be attributable to more than one mechanism, as 
witnessed by its diverse biologic properties, including the down-regulation of plasmin 
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activity, inhibition of neutrophil migration, as well as antiresorptive properties, much 
research is needed to clarify its physiologic role in wound healing among humans 71-73.  
And though the role of endogenous TSG-6 in inflammation requires further 
investigation, its potent anti-inflammatory effect suggests a role for TSG-6 in a negative 
feedback control of the inflammatory response. 
I.7 Rodent Model  
 Efforts to contribute new knowledge in biological sciences, including 
periodontology, have come not only from human sources, but from animal models and 
cell cultures.  Rodents, in particular, provide unique characteristics to evaluate microbial 
and host responses to compliment primate and human periodontal studies 74.  Rats and 
mice are the most commonly used animals in research and testing.  In fact, rats and mice 
account for approximately 90% of all mammals used in scientific endeavors.  The 
commercial availability, plus their small size, high reproductive rate, and minimal costs 
for purchase and maintenance have made them the most commonly used laboratory 
animal species. The contribution of animal studies to our understanding of medicine has 
proven vital. They have enabled researchers to unveil new insights in clinical 
experiments, which could otherwise not be performed on humans for ethical or logistical 
reasons.  
I.8 Aim 
 This study is designed to test the hypothesis that TSG-6 protein will decrease the 
acute inflammatory response following gingival wounding in a rat model. This 
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experiment could provide valuable data on the feasibility of using TSG-6 for human 
clinical studies. 
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CHAPTER II  
ANTI-INFLAMMATORY PROTEIN TSG-6 PROMOTES EARLY GINGIVAL 
WOUND HEALING: AN IN VIVO STUDY 
 
II.1 Synopsis 
 
II.1.1 Background 
 
 Human multipotent mesenchymal stromal cells (hMSCs) produce TNF-α-
stimulated protein 6 (TSG-6).  TSG-6 modulates proinflammatory cytokine cascades and 
enhances tissue repair.  This study tested the effects of recombinant human (rh) TSG-6 
on gingival wound healing within the first 2 days post-surgery. 
II.1.2 Methods 
 Following gingival resection in 120 Sprague-Dawley rats, 2 µg rhTSG-6 in 5 µL 
of phosphate buffered saline (PBS) or the same volume of PBS solution was injected 
into gingival tissue approximating the surgical wound.  Control animals did not receive 
injections.  Tissue biopsies and blood were collected at 1-2, 6-8, 24 and 48 hrs post-
surgery (n=10 per group). Specimens were analyzed via histological analysis and 
enzyme-linked immunosorbent assays (ELISA) for quantification and comparison of 
inflammatory markers IL-1β, IL-6, TNF-α and myeloperoxidase (MPO).  Photographs 
were taken for a double blind clinical assessment at each time period. Weights were 
recorded for all animals pre- and post-surgery. 
II.1.3 Results 
 Animals injected with rhTSG-6 had significantly less severe clinical 
inflammation at 6-8 (p=0.01228), 24 (p=0.01675), and 48 hours (p=0.0186).  Sham and 
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control animals had more weight loss at 24 and 48 hours.  Sham and control animals had 
more pronounced cellular infiltrate.  rhTSG-6 treated animals had significantly less 
myeloperoxidase (MPO) (p=0.027) at 24 hours and IL-1β (p=0.027) at 24 & 48 hours. 
IL-6 showed marginal significant difference at 6-8 hours, but there was no significant 
difference for TNF-α. 
II.1.4 Conclusion 
 rhTSG-6 reduced post-operative gingival inflammation by reducing levels of 
proinflammatory cytokines and cellular infiltrate and may offer significant promise as an 
anti-inflammatory agent for gingival surgery.  
II. 2 Introduction 
 Inflammation is the body’s normal protective response to an injury, irritation, or 
surgery.  Acute inflammation refers to a response that is abrupt in onset and of short 
duration.  If the cause of the initial injury is not completely eliminated, acute 
inflammation will gradually give way to chronic inflammation, though no definitive time 
sequence.  
 The acute inflammatory response has three major components: hemodynamic 
changes, alterations in the permeability of vessels, and changes in the location and 
concentration of white blood cells4.  Injury to tissues triggers a specific acute response 
that involves an exudative reaction of fluid, serum proteins, and leukocytes that leave the 
blood stream to enter the area of inury, often causing symptoms of pain, heat, redness 
and swelling. The events of the vascular response to injury, which also include release of 
polypeptide cytokines and growth factors from peripheral blood monocytes, aim to 
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localize and eliminate the injurious agents and remove damaged tissue components so 
the body can begin to heal. 
 Human adult stem/progenitor cells from bone marrow, referred to as 
mesenchymal stem cells or multipotent mesenchymal stromal cells (hMSCs), have been 
at the forefront of modern research.  Throughout their course of study, evolving data has 
led to the development of various hypotheses regarding their role in wound repair.  
Among their therapeutic factors, MSCs express the multipotent anti-inflammatory 
protein tumor necrosis factor (TNF)-α-stimulated gene/protein 6 in response to tissue 
injury 47. 
 TNF-α-stimulated gene/ protein 6, or simply TSG-6, is a hyluronan (HA)-binding 
protein that has since been implicated in the negative regulation of inflammatory tissue 
destruction.   TSG-6 DNA was originally isolated from a cDNA library prepared from 
TNF-α - treated human fibroblasts 49.  It is secreted by various cells, such as fibroblasts, 
upon stimulation by the proinflammatory cytokines tumor necrosis factor or interleukin 
1.  The rapid upregulation of TSG-6 in the presence of the pro-inflammatory cytokines 
TNF and IL-1 is consistent with its involvement in inflammatory processes 58.  This 
association was confirmed by the detection of TSG-6 protein in synovial fluids of 
patients with a variety of conditions including rheumatoid arthritis, osteoarthritis, 
Sjögren’s syndrome, polyarthritic gout, and osteomyelitis 59.  There are no studies to 
date that evaluate the properties of TSG-6 on gingival inflammation.  Therefore, this 
study aims to test the effects of recombinant human (rh) TSG-6 on early gingival wound 
healing in an animal model.    
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II.3 Materials and Methods 
 The experimental model used in this study involved the creation of an acute 
inflammatory lesion; localized to the in the maxillary and mandibular gingival tissue in a 
rat model. The hyluronan (HA)-binding protein, rhTSG-6 (purchased from R & D 
Systems), was used to test its anti-inflammatory effects following injury. This protocol 
was submitted for review and approved by the Institutional Animal Care and Use 
Committee at Baylor College of Dentistry – a member of Texas A&M University 
System. 
II.3.1 Study Animals 
 One hundred twenty, adult male (DOB:12/14/12), Sprague Dawley rats, (Harlan 
Laboratories),  weighing approximately 400 grams were used in this study in an attempt 
to minimize interspecies variance.  All animals were housed in individual polycarbonate 
cages and provided with standard rat chow pellets and water ad libitum.  Rats were 
separated into three groups (experimental, sham, control) and were numbered for 
identification purposes via tail markings.  All animals were given a 7-day acclimation 
period with a 12-hour light/12-hour dark cycle.  Rats were monitored daily throughout 
the experimental period.  General anesthesia was induced by administering Ketamine 
(0.08mL/100g) and Xylazine (0.04mL/100g) intramuscularly.  Following onset of 
anesthesia, the animals were weighed and placed on a surgical table.  An aseptic surgical 
technique was utilized.  All protocols for anesthesia, post-operative care, and necropsy 
of the animal subject were approved by the Institute of Animal Care and Use Committee 
prior to commencement of study. 
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II.3.2 Surgical Procedures 
 Ketamine (0.08mL/100g) and Xylazine (0.04mL/100g) were combined for use as 
a general anesthetic and given as an intraperitoneal injection using a 1 ml syringe 23-25 
gauge 5/8 inch needle.  All rats were weighed prior to surgical procedures.  Animals 
were numbered and divided among three groups: 
Group 1: Experimental (40 animals)—gingivectomy + TSG-6 
Group 2: Sham (40 animals)—gingivectomy + PBS 
Group 3: Control (40 animals)—gingivectomy 
 Using a Miltex stainless steel disposable #12 scalpel, under 3.5x magnification 
via dental loupes, a standardized gingival wound was produced in one hundred and 
twenty animals.  The wound consisted of a gingivectomy performed on the mandibular 
and maxillary anterior marginal and attached gingiva, removing a triangular piece of 
tissue between the central mandibular and maxillary incisors.  Incisions were performed 
at an angle of 45° and at 2mm from each tooth surface.  All measurements were made 
with a Hu-Freidy PCPUNC15 perio probe (Figure 1, A).  The scalpel was inserted in the 
keratinized tissue so as to obtain a complete surgical transection of the gingiva (Figure 1, 
B).  A Gracey 11-12 curette was utilized to remove excised gingival tissue.  Immediately 
after tissue removal, 2 µg recombinant human TSG-6 (rhTSG-6) in 5 µL of PBS solution 
was injected into the gingival tissue approximating the surgical wound in forty 
experimental rats (Group 1).  The depth of needle insertion, for delivery of the solution, 
was standardized using a rubber stopper 1 mm from the needle point (Figure 1, C).  
Injections were made with a 3/10cc insulin syringe 29 guage ½” needle.  The same 
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volume of PBS solution was injected into the gingival tissue in forty additional rats 
(Group 2).  The forty control animals (Group 3) were not injected following 
gingivectomy.  All animals (Groups 1, 2 & 3) were assessed at 4 different time points: 
1-2 hrs: 10 animals  
6-8 hrs: 10 animals  
 24 hrs: 10 animals  
 48 hrs: 10 animals  
Intra oral photographs were taken of all animals at time of sacrifice.  
II.3.3 Specimen Recovery Procedures 
 At the time points allocated (1-2, 6-8, 24, and 48 hrs) post-surgery, all animals 
per specified group were euthanized.  Euthanasia was accomplished via CO2 chamber, 
for ease of handling, prior to decapitation.   Weights were recorded for all animals before 
decapitation.   
 At the time of sacrifice, blood was collected into test tubes from each animal.  
Samples were placed on ice into 15ml polypropylene tubes with 0.5M EDTA. Blood was 
spun down at 3000 rpm for 20 minutes.  Plasma was collected and frozen at -20°C until 
further analysis of inflammatory markers could be assessed via ELISA assays.   
Random allocation performed prior to surgery determined the distribution of maxillary 
and mandibular gingival tissue per method of analysis – histology or myeloperoxidase 
assay (MPO).   
 Tissue specimens were obtained from the incisional border at the site of injury 
with a 4mm Tru-Punch sterile disposable biopsy punch (Sklarcorp) (Figure 2).  
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Maxillary and mandibular specimens were separated, according to randomization chart, 
and placed into bottles labeled for histopathology, containing 4% paraformaldehyde, or 
MPO assay.  All specimens were frozen until termination of all surgical procedures.   
II.3.4 Gingival Surface Evaluation and Clinical Outcome Analysis 
 At the time of sacrifice, gingival wounds in the mandibular arch were 
photographed utilizing a Digital SLR camera with a DG 105 mm f/2.8 Macro EX Sigma 
Lens at a distance of approximately 12 inches from the specimen.  Four photographs 
from each group, from each time point, were selected for clinical evaluation.  Each 
photograph was then assigned a number corresponding to the degree of inflammation 
observed by 18 blinded volunteers comprised of periodontists and periodontal residents.  
All volunteers were given an initial description and photograph corresponding to the 
severity of inflammation to be observed.  Subjects were asked to determine the severity 
of gingival inflammation using criteria presented to each subject before the survey. 
Severity was determined on a 3-point  – (1) mild, (2) moderate, and (3) severe.    
The assessment criteria provided, is as follows: 
1 = mild inflammation or with slight changes in color and texture but not in all portions 
of marginal or papillary gingiva.  Non-bleeding. 
2 = moderate, bright surface inflammation, erythema, edema and /or hypertrophy of 
marginal or papillary gingiva. 
3 = severe inflammation; erythema, edema and/or gingival hypertrophy of the unit or 
spontaneous bleeding, papillary, congestion or ulceration. 
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II.3.5 Histological Processing/ELISAs 
 Individual specimens were prepared for histological analysis using standard 
procedures for biopsy specimens.  Tissue samples were fixed in 4% paraformaldehyde at 
4oC.  After dehydration, specimens were immersed in paraffin and processed for 
sectioning. Paraffin embedded specimens were sectioned at 5 microns thickness.  Slides 
were stained with hematoxylin and eosin and studied under light microscope. 
 Tissue for ELISA testing was homogenized in 500ul TPER with HALT + EDTA 
as a protease inhibitor.  Specimens were spun down for 20 minutes at 4oC 3000rpm.  
Supernatant was then pulled off and frozen at -20C until used for ELISA analysis. 
II.3.6 Statistical Analysis 
 Before the initiation of this study, the sample size was determined to be 10 
animals per  treatment group per time point based on a power test with α = 0.05.  A 
Difference Z-test was performed on pre-surgical weight (PreSW) versus post-surgical 
weight (PostSW). Weights were tested separately and plotted using a boxplot.  
Simultaneous paired t-tests were performed to determine between which groups 
exhibited a significant difference. To analyze the presence of significant differences for 
each protein and enzyme at each point of time between each subgroup a Kruskal-Wallis 
Rank Sum Test for Two-Sided One-Way ANOVA was performed.  For all tests level of 
marginal significance is .05 ≤ α ≤ .1, and the level of significance α ˂ .05.  The survey 
data was analyzed using Kruskal-Wallis Rank Sum Test.  A plot with associated p-
 38 
 
values at each time category was produced.  Because the data is nonparametric, and n˂4, 
the Mann-Whitney two sample comparison test was forgone.   
II.4 Results 
II.4.1 Clinical Assessment 
 From the time of gingivectomy until the time of sacrifice (hrs to days), no signs 
of infection or adverse healing were noted.  Clinical evaluation at the time of sacrifice 
for the 1-2 hour group revealed erythematous and edematous gingival tissue.  Tissues 
continued to appear inflamed and swollen at 6-8 hours post-surgery.  By 24 hours, 
gingiva appeared moderately erythematous.  An early wound covered with a blood clot 
was generally present.  At 48 hours, gingival tissue appeared generally pink and non-
bleeding. Results of the survey data are presented on Figure 3.  The means of each group 
at each time point were plotted.  Overall, the data conclusively indicates that at each time 
point, Group 1 (TSG-6) showed lower inflammation as a result of visual analysis by the 
subjects at 6-8 hrs (p=0.01228), 24 hrs (p=0.01675), and 48 hrs (p=0.01806).  There was 
a significant difference between Group 1(TSG-6) and Group 2 (PBS) (p<0.001) and a 
significant difference between Group 1 and Group 3 (Control) (p=0.016).  Additionally, 
Group 2 showed the highest levels of inflammation at all points.  Unexpectedly, Group 3 
showed an unusual score increase between 6-8 hrs and 24 hrs.   
II.4.2 Weights 
 All animals were weighed at baseline and at time of sacrifice.  The mean weights 
for the 24-hr and 48-hr group were tabulated.  The difference from the mean pre-surgical 
to post-surgical weights for the 24-hr Group 1 (TSG-6), Group 2 (PBS) and Group 3 
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(Control) were 1.8, 8.9, and 10.8 grams, respectively.  The difference from the mean pre-
surgical to post-surgical weights for the 48-hr Group 1 (TSG-6), Group 2 (PBS) and 
Group 3 (control) were 5.7, 12.1, and 11.8 grams, respectively.  The mean with a 95% 
confidence interval was tabulated for all animals and presented in Figure 4.  It is evident 
that overall, post-surgical weights were lower than pre-surgical weights.   Differences in 
mean weights were -3.8, -11.1, and -16.3 for Group 1, 2 and 3, respectively.  A box plot 
comparison of the differences in pre-surgical and post-surgical weights versus group 
illustrates that the Group 1 (TSG-6) showed a lower loss in weight (calculated as 
              ) than the other two groups (Figure 4).  Additionally, simultaneous 
paired t-tests were performed to determine between which groups exhibited a significant 
difference post-surgically.  There was a significant difference between Group 1 (TSG-6) 
and Group 2 (PBS) (p < .001) and a significant difference between Group 1 and Group 3 
(Control) (p = . 016).  There was no significant difference between Groups 2 & 3. 
II.4.3 Histology 
 Three tissue specimens per treatment group and time point were analyzed.  
Specimens chosen for histologic analysis were obtained from the same animals utilized 
in the visual assessment examination.  H & E stain showed similar amounts of cellular 
infiltrate at 1-2 hours post- surgery.  Cellular infiltrate increased over the subsequent 
hours analyzed.  Generally, Groups 2 & 3 (PBS & Control) showed markedly more 
infiltrate compared to Group 1 (TSG-6) at 6-8, 24, and 48 hours (Figure 5).  
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II.4.4 ELISAs 
 Myeloperoxidase (MPO) assay revealed an increase in MPO levels between 1-2 
hours and 24 hours, but a slight decrease between 24 and 48 hours.  All MPO levels 
showed similar values at the 1-2 hour time point, and thus showed no significant 
difference.  There were marginal significant differences noted at 6-8 and 48 hours 
(p=0.66) and a significant difference between the three groups at 24 hours (p=0.027). 
Group 1 showed a 43.8% reduction in MPO levels at 24 hours when compared to Group 
3.  The group treated with TSG-6 had the lowest levels between 6-8 and 24 hours.  The 
control group showed the highest level of MPO for 24 to 48 hours. For each data point 
n=3 (Figure 6). 
 Blood samples for Interleukin 1β (IL-1β) were analyzed via ELISA; however, 
levels of IL-1β were not detectable, indicating no systemic involvement.   Tissue 
samples were therefore utilized to assess cytokine levels.  Data revealed an increase in 
IL-1β between 1-2 and 24 hours, but decrease between 24 and 48 hours except Group 1.  
The test showed no significant difference at the initial point, 1-2 hours (p=0.670), but 
there were marginal significant differences at 6-8 hours (p=0.051), and a significant 
difference between the three groups at 24 and 48 hours (p=0.027). Group 1 showed a 
68.0% reduction in levels of IL-1β at 24 hours when compared to Group 3.  Overall, the 
group treated with the TSG-6 has the lowest levels between 6-8 hours, 24 hours, and 48 
hours. For each data point n = 3 (Figure 6).   
 Interleukin 6 (IL-6) was elevated between 1-2 hours and 6-8 hours, but there was 
a decrease in IL-6 levels between 6-8 hours and 24 hours and between 24 hours and 48 
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hours.  Overall, the group treated with TSG-6 had the lowest levels between 6-8 hours 
and 24 hours. The control group showed the highest level of IL-6 for 6-8, 24, and 48 
hours. There was a marginal significant difference at 6-8 hours (p=0.099) (Figure 6). 
Group 1 showed a 50.9% reduction in levels of IL-6 at 6-8 hours when compared to 
Group 3. 
II.5 Discussion 
 Healing of periodontal tissue after surgical treatment has long been a subject of 
interest.  In the current study, the anti-inflammatory effects of tumor necrosis factor-α-
stimulated gene protein 6 (TSG-6) was evaluated following injection into an acute 
gingival wound in Sprague-Dawley rats.  Within the limits of this study, injection of 2 
µg TSG-6 was found to accelerate wound healing by reducing inflammatory cell 
infiltrate and reducing cytokines IL-1β and IL-6.  Significant differences were seen at 6-
8, 24, and 48 hours, as observed clinically and microscopically.   
 Similar findings have been reported when 2µg TSG-6 were injected into the 
anterior chamber of rats’ eyes following mechanical injury 66.  In addition, TSG-6 
reduced corneal inflammation and opacity in a dose-dependent manner.  In transgenic 
mice, its anti-inflammatory effects were observed when an over expression of the gene 
decreased inflammation and joint destruction following induced arthritis 64.  Likewise, 
TSG-6 was associated with a lower density of macrophages and infiltrating leukocytes, 
reduced levels of pro-inflammatory cytokines, and increased levels of anti-inflammatory 
cytokines following infusion of MSCs into the CNS of post traumatic brain injuries in 
rats75.   The anti-inflammatory activity of TSG-6 has been attributed to its ability to 
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suppress neutrophil migration into the site of inflammation and inhibit components in 
the inflammatory network of proteases. 69 
 The present study showed that intra-gingival injection of rhTSG-6 decreased the 
infiltration of neutrophils, pro-inflammatory cytokines, and reduced clinical signs of 
inflammation following gingival transection within the first 2 days following surgery. 
 All rats were weighed pre-surgically and post-surgically immediately prior to 
decapitation.  Weight differences were analyzed and compared between 24 and 48 hour 
groups.  Simultaneous t-tests were performed to determine between which groups 
existed a significant difference.  All animals injected with TSG-6 showed less weight 
loss compared to animals not injected with TSG-6.  Animals not injected with the 
protein evidently ate less or stopped eating after surgery, indicating that in addition to 
decreasing inflammation, TSG-6 may have some influence on pain perception.  Pain is a 
subjective sensation.  From the site of injury, impulses travel to the central nervous 
system and to higher centers of the brain responsible for determining the magnitude of 
pain.  Vasodilation and increases in vascular permeability at the site of injury result in 
heat, redness, and swelling; while exuded fluid produces pressure on sensory nerve 
endings. Pain in an animal is often inferred from the absence of normal behaviors such 
as alertness, mobility, groomed coat, or a good appetite 76.  One can speculate that the 
animals that received TSG-6 were experiencing less pain/ discomfort, primarily 
associated with a reduced state of inflammation, and subsequently were able to maintain 
their eating habits compared to control animals.     
 Within hours of injury, inflammatory cells (predominantly neutrophils and 
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monocytes) populate the clot.  These cells cleanse the wound of microorganisms and 
necrotic tissue via phagocytosis and release of enzymes and toxic oxygen products 77. 
Histologically, cellular infiltrate was less pronounced in specimens obtained from 
animals receiving rhTSG-6 injections, most notably at 6-8, 24 and 48 hours.   
 In this study, quantification of neutrophils was assessed both morphologically 
and biochemically.  Myeloperoxidase (MPO), released from the granules of neutrophils 
and monocytes in response to the activation of leukocytes plays an important role in 
several inflammatory conditions.  MPO is a lysosomal protein that produces 
hypochlorous acid (HOCl) from hydrogen peroxide and chloride anion.  The neutrophil 
uses the hypochlorous acid, which is cytotoxic, to kill bacteria and other pathogens.  
Hypochlorous acid is an extremely powerful oxidant that rapidly attacks a wide range of 
target molecules.  For a quantitative measure of neutrophil infiltration, gingival 
specimens were assayed for MPO concentration.   Because TSG-6 has been shown to 
directly suppress neutrophil infiltration, assessment of MPO concentration was chosen 
for evaluation, as opposed to C-reactive protein (CRP).  CRP is an acute phase protein 
synthesized by the liver in response to factors released predominately by macrophages 
and fat cells.  As anticipated, TSG-6 had significantly decreased levels of MPO in the 
gingiva.  This finding correlates with our histological observations; reduced cellular 
infiltrate in specimens injected with TSG-6.   
 A similar pattern was observed in data obtained by assays of the tissue for 
expression of proinflammatory cytokines.    The expression of proinflammatory 
cytokines, IL-1β and IL-6, were markedly reduced by TSG-6 treatment.  Similar findings 
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in expression of cytokine levels were seen when TSG-6 was injected into the eyes of rats 
following injury 66.  Neutrophils, monocytes, and other cells produce innate immune 
cytokines such as IL-1, IL-6, and TNF-α after being summoned to the site of injury by 
chemokines.  In this study, levels of TNF-α (data not shown) were undetectable.  These 
findings parallel those of Oh et al and colleagues. In their study, TNF-α was not detected 
in treated or untreated corneas by ELISA or real-time PCR analysis 66.  TNF-α, while 
known to stimulate the acute phase reaction, is produced chiefly by activated 
macrophages.  It is a potent chemoattractant for neutrophils and promotes the expression 
of adhesion molecules on endothelial cells.  Inconsistencies with other data sets in this 
study remain unclear.  
 In addition, it is of interest that intragingival injection of TSG-6 had no effect on 
plasma cytokine levels as determined by ELISA, indicating intra-gingival injection of 
2µg rhTSG-6 had no systemic involvement.  TSG-6 acted locally on tissues to down 
regulate inflammatory mediators.  This is in contrast to earlier findings by Getting et al 
and colleagues in which as little at 1 µg TSG-6 was administered at a site remote from 
the inflammatory environment.  Reductions in neutrophil influx and inhibitions of IL-1β 
were observed 67.  Their findings suggest that TSG-6 does not need to be given local to 
the site of inflammation but, rather, acts via the circulation.  Further studies are needed 
to corroborate these findings. 
 The mechanism of action observed by the anti-inflammatory effects of TSG-6 is 
not well understood.  However, in recent studies, Inter-α-inhibitor, an abundant plasma 
protein with anti-proteolytic activity, consisting of three polypeptides: two heavy chains 
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and one light chain, has been shown to bind to hyaluronon molecules via covalent bonds; 
a reaction thought to be mediated by TSG-6.  TSG-6 has been shown to be tightly bound 
to the hyaluronon-linked heavy chains.  This complex has been implicated in stabilizing 
extracellular matrix by cross-linking hyaluronan molecules and protect hyaluronan 
against fragmentation by reactive oxygen species, enhancing tissue repair 70.  Though the 
anti-inflammatory properties are likely to be attributable to more than one mechanism, as 
witnessed by its diverse biologic properties, including the down-regulation of plasmin 
activity, inhibition of neutrophil migration, as well as antiresorptive properties, much 
research is needed to clarify its physiologic role in wound healing among humans 71-73.   
 Inflammation, though protective in nature, can cause cellular damage if not 
controlled.  For instance, neutrophil granules contain more than 20 proteolytic enzymes, 
of these, elastase, collagenase, and gelatinase have the greatest potential to act as 
mediators of tissue destruction 5.  These enzymes are able to attack extracellular matrix.  
In addition, hypochlorous acid, induced by myeloperoxidase, can inactivate key 
proteinase inhibitors while activating latent neutrophil proteinases.  Lysosomal enzymes 
also become susceptible to host tissue.  Leakage of lysosomal enzymes during 
phagocytosis or cell death may result in tissue damage.  Reverse endocytosis and 
regurgitation during feeding (phagocytosis) may also permit release of these lytic 
enzymes into surrounding tissues 5.  Damage to host tissue is almost inevitable.  Efforts 
to control or limit the inflammatory burden are paramount in restoring the body to 
health. 
 Resective surgeries in non-inflamed tissue are common practices in the field of 
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periodontics for treatment of altered passive eruption, over grown gingiva, crown 
lengthening, gingival recontouring, gingival flap retraction for access to impacted 
teeth/roots, or for implant placement.  Extension of the incision as well as tissue 
manipulation and length of surgery could affect the extent of swelling. Post-operative 
discomfort resulting from swelling and pain following different surgical strategies is an 
area of great interest.  Attention has been focused on non-steroidal anti-inflammatory 
drugs (NSAIDs) and corticosteroid therapy administered by diverse routes (orally, IM, 
IV, topically) before or after surgery.  Side effects of corticosteroids include, but are not 
limited to hyperglycemia, adrenal insufficiency, and reductions in immune response.  
Efforts to find new anti-inflammatory agents that reduce post-operative discomfort are 
well underway.   
 Future studies are needed to investigate and substantiate our prediction that TSG-
6 decreases pain as well as inflammation.  Placing animals into feeding chambers and/or 
analyzing pain pathways and alternations thereof could provide significant insight into 
the molecular mechanisms of TSG-6.  Replications of these experiments with larger 
treatment groups would be of great value.  This study, though primitive in nature and 
small in sample size, demonstrates that a single intragingival injection of TSG-6 reduced 
local post-operative inflammation, limiting destruction of the tissue by the normal but 
excessive inflammatory response to a sterile injury.   
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CHAPTER III  
CONCLUSION  
 To the best of our knowledge, this is the first invivo study to compare the clinical 
and histological effects of TSG-6 on gingival inflammation in an animal model.  Within 
the limits of the study, injection of 2µg rhTSG-6 significantly reduced post-operative 
inflammation by decreasing levels of proinflammatory cytokines IL1β  (68%) and IL-6 
(50.9%) , neutrophil infiltration (43.8%) , erythema, and bleeding within the first few 
hours and days after injury.  TSG-6 offers substantial promise for patients undergoing 
gingival resective surgery.  
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APPENDIX 
Figure 3. Surgical Procedure 
 
 
A. Pre-Surgical Measurements  
(PCPUNC15 perio probe) 
  
       
 
 
B. Surgical Transection of the Gingiva  
(Miltex stainless steel disposable #12 scalpel) 
 
 
       
 
 
 59 
 
Figure 3. Continued 
 
 
C. Injecting 2µg TSG-6/ PBS Solution 
(3/10cc insulin syringe U-100 29g ½” needle w/ rubber stopper 1 mm from tip end) 
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Figure 4. Specimen Collection 
(4mm Tru-Punch sterile disposable biopsy punch) 
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Figure 5. Clinical Assessment 
 
 
A. 24 HRS Post-Surgery.  
Group 1 (rh TSG-6), 2 (PBS), 3 (CONTROL); respectively. 
 
                              
   
 
 
B. 48 HRS Post-Surgery.  
Group 1 (rh TSG-6), 2 (PBS), 3 (CONTROL); respectively. 
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Figure 5. Continued 
 
 
C. Mean Score With Respect To Time By Group 
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Figure 6.  Box Plot Comparison 
 
 
 
 
Mean Weights (g) with (Lower Confidence Interval, Upper Confidence Interval) 
 Pre Surgery (PreSW) Post Surgery (PostSW) Difference (D) 
Group 3 
Control 412.6 (365.4, 459.8) 396.3 (371.9, 420.7) -16.3 (-66.9,34.3) 
Group 2 PBS 401.9 (381.0,422.7) 390.8 (369.4, 412.1) -11.1 (-23.2, 1.0) 
Group 1 TSG-6 398.2 (370.1, 426.2) 394.4 (366.4, 422.4) -3.8 (-10.7, 3.2) 
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Figure 7. Histology 
H & E stain of specimens per treatment group per time point 
 
                               TSG-6                         PBS                      Control 
1 -2 hrs                           
6-8 hrs        
24 hrs         
48 hrs          
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Figure 8. ELISAs 
 
 
A. MPO Assay 
Units of MPO are 
  
  
 of protein 
 
 
 
 
 
B. IL-1β 
Units of IL-1β are 
  
  
 of protein 
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Figure 8. Continued 
 
 
C. IL-6 
Units of IL-6 are 
  
  
 of protein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
